A Look At Insmed (INSM) Valuation After Positive ENCORE Phase 3b ARIKAYCE Data [Yahoo! Finance]
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
Insmed (INSM) is back in focus after reporting positive topline data from its Phase 3b ENCORE study of ARIKAYCE in newly diagnosed MAC lung infection, an event that coincided with a sharp move in the stock. See our latest analysis for Insmed. The latest ENCORE data drop comes after a mixed stretch for the stock, with a 1 day share price return of 5.87% to US$143.98, but a 30 day share price return decline of 12.69%. This comes alongside a very large 3 year total shareholder return that highlights how much of the story has already been priced in over a longer horizon. If this kind of biotech catalyst has your attention, it can be worth seeing what else is on the move in healthcare, including 36 healthcare AI stocks With Insmed now valued at about US$29.3b after a very large 3 year total shareholder return, and the shares sitting roughly 19% below their recent high, the key question is whether this pullback signals a fresh entry point or if the market is already factoring in th
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed (INSM) had its price target raised by Stifel Nicolaus from $205.00 to $208.00. They now have a "buy" rating on the stock.MarketBeat
- Insmed eyes Arikayce label expansion on Phase IIIb lung disease success [Yahoo! Finance]Yahoo! Finance
- Insmed (INSM) had its price target raised by Bank of America Corporation from $211.00 to $213.00. They now have a "buy" rating on the stock.MarketBeat
- Insmed CEO on its Arikayce drug after shares surge on trial results [CNBC]CNBC
- Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript [Seeking Alpha]Seeking Alpha
INSM
Earnings
- 2/19/26 - Miss
INSM
Sec Filings
- 3/23/26 - Form 8-K
- 3/20/26 - Form 4
- 3/19/26 - Form 144
- INSM's page on the SEC website